Morphology builds on NovaSignal’s mission to unlock the power of cerebral blood flow data for all healthcare practitioners
NovaGuide, the only autonomous transcranial Doppler ultrasound, is approved for use in Canada.
Clinical trial data presented in late-breaking science session at the American Heart Association International Stroke Conference 2022 show NovaGuide is three times more likely to detect RLS than standard of care transthoracic echocardiography.
NovaSignal secures $37 million in series C1. Funding will enable further commercial growth and the expansion of clinical trials.
NovaSignal Corp. announced today that its board of directors has appointed Mark R. Laret as an independent director, effective August 5, 2021. Mr. Laret is president and chief executive officer of UCSF Health.
The NovaGuide™ 2 Intelligent Ultrasound and NovaGuide View cloud-based software make complex cerebral assessments easy to perform and enable faster time to treatment with on-demand access to exam data
Technology industry veteran, Andy D. Bryant, to help drive company growth and advise technology innovation
As NovaSignal extends the reach and impact of its solutions worldwide, the company is adding to its capabilities and expertise with the appointment of Lynne Doughtie, former Chairman and CEO of KPMG LLP, to the Board of Advisors
As NovaSignal extends the reach and impact of its solutions worldwide, the company grows its access to deep public health expertise with the appointment of Richard Carmona, the 17th Surgeon General of the United States, to the Board of Advisors
NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, today announced enrollment of the first patient in its clinical trial evaluating the advantages of the NovaGuide Intelligent Ultrasound in detecting a patent foramen ovale (PFO) compared to traditional ultrasound methods.
NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, announced today its expansion into India.
Dr. Nicole O’Brien, a critical care physician and director of the Global Health Certificate Program at Nationwide Children’s, has spent the last six years working to understand and address acute neurologic illness and injury in children. Her years of research took her to subSaharan Africa, where up to 3% of births, or over 300,000 babies, are born with sickle cell disease each year.
NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, announced today that Gayle Sheppard is joining the Advisory Board, effective Sep 7, 2020.
NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, announced today that its board of directors has appointed John M. Donovan as an independent director, effective Wednesday, August 26th. Donovan most recently served as CEO of AT&T Communications.
While monitoring these critically ill patients with the Lucid™ Robotic System, physicians discovered an overabundance of pulmonary shunting, a physical dysfunction whereby deoxygenated blood bypasses the normal circulatory system resulting in lower levels of oxygen in the blood and contributing to respiratory distress in patients with COVID-19.
Medical technology and data company Neural Analytics, Inc. announced a name change and rebranding as NovaSignal Corp., representing its expansion into new markets and accelerated commercialization of its life-saving solutions that measure blood flow in the brain.
Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announced today it has appointed former Google Cloud COO Diane M. Bryant as Chairman and CEO, effective immediately. Leo Petrossian has resigned from his position as CEO and will be maintaining his company role as Co-Founder and President.